Blueprint Medicines Corp (NASDAQ:BPMC) Expected to Announce Quarterly Sales of $3.75 Million

Equities analysts predict that Blueprint Medicines Corp (NASDAQ:BPMC) will post sales of $3.75 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Blueprint Medicines’ earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $6.50 million. Blueprint Medicines posted sales of $41.44 million during the same quarter last year, which suggests a negative year-over-year growth rate of 91%. The company is scheduled to report its next quarterly earnings results on Wednesday, August 7th.

According to Zacks, analysts expect that Blueprint Medicines will report full-year sales of $8.90 million for the current financial year, with estimates ranging from $3.90 million to $20.00 million. For the next financial year, analysts expect that the business will post sales of $42.62 million, with estimates ranging from $17.48 million to $62.62 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Blueprint Medicines.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($1.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.15). The firm had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.38 million. Blueprint Medicines had a negative return on equity of 59.26% and a negative net margin of 603.88%. Blueprint Medicines’s revenue was down 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.29) earnings per share.

A number of research firms recently issued reports on BPMC. BidaskClub lowered Blueprint Medicines from a “buy” rating to a “hold” rating in a report on Thursday. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Monday, June 17th. ValuEngine raised Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 4th. Goldman Sachs Group reissued a “buy” rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Thursday, May 23rd. Finally, Zacks Investment Research raised Blueprint Medicines from a “hold” rating to a “buy” rating and set a $88.00 price target on the stock in a research note on Tuesday, April 30th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $105.83.

NASDAQ:BPMC opened at $94.33 on Friday. The business’s 50-day moving average price is $85.54. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of -17.50 and a beta of 1.45. Blueprint Medicines has a 52-week low of $44.58 and a 52-week high of $100.76. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.27.

In related news, CEO Jeffrey W. Albers sold 20,000 shares of Blueprint Medicines stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $84.75, for a total value of $1,695,000.00. Following the transaction, the chief executive officer now owns 48,961 shares of the company’s stock, valued at approximately $4,149,444.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ariel Hurley sold 2,733 shares of Blueprint Medicines stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $88.04, for a total value of $240,613.32. The disclosure for this sale can be found here. Insiders sold a total of 79,044 shares of company stock worth $7,077,431 in the last three months. 3.15% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in BPMC. Rhumbline Advisers increased its stake in shares of Blueprint Medicines by 46.1% in the fourth quarter. Rhumbline Advisers now owns 55,349 shares of the biotechnology company’s stock worth $2,984,000 after acquiring an additional 17,475 shares during the period. Comerica Bank increased its stake in shares of Blueprint Medicines by 20.9% in the fourth quarter. Comerica Bank now owns 12,617 shares of the biotechnology company’s stock worth $878,000 after acquiring an additional 2,180 shares during the period. First Trust Advisors LP acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $1,390,000. Dimensional Fund Advisors LP acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $1,352,000. Finally, Foresite Capital Management III LLC increased its stake in shares of Blueprint Medicines by 133.8% in the fourth quarter. Foresite Capital Management III LLC now owns 467,682 shares of the biotechnology company’s stock worth $25,213,000 after acquiring an additional 267,682 shares during the period. 97.46% of the stock is currently owned by institutional investors.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Featured Story: What do investors mean by earnings per share?

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.